MCID: ART008
MIFTS: 45

Arteriosclerosis Obliterans

Categories: Cardiovascular diseases

Aliases & Classifications for Arteriosclerosis Obliterans

MalaCards integrated aliases for Arteriosclerosis Obliterans:

Name: Arteriosclerosis Obliterans 12 36 51 41 14 69
Arteriosclerosis Obliterans [ambiguous] 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5160
MeSH 41 D001162
SNOMED-CT 64 361133006 60625000
KEGG 36 H01626
UMLS 69 C0003851

Summaries for Arteriosclerosis Obliterans

MalaCards based summary : Arteriosclerosis Obliterans, also known as arteriosclerosis obliterans [ambiguous], is related to arteriosclerosis and peripheral artery disease. An important gene associated with Arteriosclerosis Obliterans is SELP (Selectin P), and among its related pathways/superpathways are Cytokine Signaling in Immune system and HTLV-I infection. The drugs Aspirin and Cilostazol have been mentioned in the context of this disorder. Affiliated tissues include heart, bone and bone marrow, and related phenotypes are cardiovascular system and cellular

Wikipedia : 72 Arteriosclerosis obliterans is an occlusive arterial disease most prominently affecting the abdominal... more...

Related Diseases for Arteriosclerosis Obliterans

Diseases related to Arteriosclerosis Obliterans via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 89)
# Related Disease Score Top Affiliating Genes
1 arteriosclerosis 30.4 ADIPOQ HGF ICAM1 IL6 SELP VCAM1
2 peripheral artery disease 30.2 IL6 SELP VCAM1
3 intermittent claudication 30.2 IL6 SELP
4 coronary artery anomaly 30.0 ADIPOQ IL6 SELP
5 peripheral vascular disease 30.0 IL6 SELP VCAM1
6 chronic venous insufficiency 29.9 ICAM1 SELP VCAM1
7 vascular disease 29.9 ADIPOQ SELP VCAM1
8 venous insufficiency 29.9 ICAM1 SELP VCAM1
9 ischemia 29.8 HIF1A ICAM1 SELP
10 arteries, anomalies of 29.6 ADIPOQ ICAM1 IL6 SELP VCAM1
11 diabetes mellitus, noninsulin-dependent 29.6 ADIPOQ IL6 SELP VCAM1
12 myocardial infarction 28.9 ADIPOQ HIF1A ICAM1 IL6 SELP
13 obesity-hypoventilation syndrome 10.4 ADIPOQ IL6
14 intermediate coronary syndrome 10.3 IL6 SELP
15 chronic eosinophilic pneumonia 10.3 ICAM1 IL6
16 nonalcoholic steatohepatitis 10.3 ADIPOQ IL6
17 lymphocytic vasculitis 10.3 ICAM1 VCAM1
18 cortical thymoma 10.3 ICAM1 VCAM1
19 hypersensitivity reaction type iii disease 10.3 ICAM1 IL6
20 mooren's ulcer 10.3 ICAM1 VCAM1
21 subendocardial myocardial infarction 10.3 ICAM1 VCAM1
22 actinic prurigo 10.3 ICAM1 VCAM1
23 post-thrombotic syndrome 10.3 ICAM1 IL6
24 prediabetes syndrome 10.3 ADIPOQ IL6
25 macular retinal edema 10.3 ICAM1 IL6
26 rheumatoid vasculitis 10.3 ICAM1 VCAM1
27 limbal stem cell deficiency 10.3 ICAM1 VCAM1
28 apnea, obstructive sleep 10.3 ADIPOQ IL6
29 henoch-schoenlein purpura 10.3 ICAM1 VCAM1
30 leukostasis 10.3 ICAM1 VCAM1
31 critical limb ischemia 10.3 HGF IL6
32 shwartzman phenomenon 10.3 ICAM1 VCAM1
33 diabetes mellitus 10.2
34 coronary artery aneurysm 10.2 ADIPOQ VCAM1
35 plasmodium vivax malaria 10.2 ICAM1 IL6
36 viral encephalitis 10.2 IL6 VCAM1
37 diabetic macular edema 10.2 ICAM1 IL6
38 buerger disease 10.2
39 aneurysm 10.2
40 heart disease 10.2
41 crescentic glomerulonephritis 10.1 ICAM1 VCAM1
42 immune-complex glomerulonephritis 10.1 ICAM1 SELP VCAM1
43 aortic aneurysm 10.1
44 sleep apnea 10.1 ADIPOQ ICAM1 IL6
45 dengue disease 10.1 ICAM1 VCAM1
46 cytomegalovirus infection 10.1 ICAM1 IL6 VCAM1
47 oral lichen planus 10.1 ICAM1 VCAM1
48 trypanosomiasis 10.1 ICAM1 IL6 VCAM1
49 synovitis 10.1 ICAM1 IL6 VCAM1
50 chronic kidney failure 10.1 ICAM1 IL6 VCAM1

Graphical network of the top 20 diseases related to Arteriosclerosis Obliterans:



Diseases related to Arteriosclerosis Obliterans

Symptoms & Phenotypes for Arteriosclerosis Obliterans

MGI Mouse Phenotypes related to Arteriosclerosis Obliterans:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.92 ADIPOQ HGF HIF1A ICAM1 IL6 MCAM
2 cellular MP:0005384 9.8 ADIPOQ HGF HIF1A ICAM1 IL6 SELP
3 hematopoietic system MP:0005397 9.76 ADIPOQ HGF HIF1A ICAM1 IL6 MCAM
4 immune system MP:0005387 9.5 SELP VCAM1 ADIPOQ HIF1A ICAM1 IL6
5 liver/biliary system MP:0005370 9.02 ADIPOQ HGF HIF1A IL6 SELP

Drugs & Therapeutics for Arteriosclerosis Obliterans

Drugs for Arteriosclerosis Obliterans (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 57)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
2
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
3
Probucol Approved, Investigational Phase 4 23288-49-5 4912
4
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
5
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
6
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
7
Remifentanil Approved Phase 4 132875-61-7 60815
8
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
9 Analgesics Phase 4
10 Analgesics, Non-Narcotic Phase 4
11 Anti-Asthmatic Agents Phase 4
12 Anti-Inflammatory Agents Phase 4
13 Anti-Inflammatory Agents, Non-Steroidal Phase 4
14 Antipyretics Phase 4
15 Antirheumatic Agents Phase 4
16 Autonomic Agents Phase 4
17 Bronchodilator Agents Phase 4
18 Cyclooxygenase Inhibitors Phase 4
19 Fibrinolytic Agents Phase 4
20 Neuroprotective Agents Phase 4
21 Peripheral Nervous System Agents Phase 4
22 Phosphodiesterase 3 Inhibitors Phase 4
23 Phosphodiesterase Inhibitors Phase 4
24 Platelet Aggregation Inhibitors Phase 4,Phase 2
25 Protective Agents Phase 4
26 Respiratory System Agents Phase 4
27 Vasodilator Agents Phase 4,Phase 2
28 Anticholesteremic Agents Phase 4
29 Antimetabolites Phase 4
30 Antioxidants Phase 4
31 Hypolipidemic Agents Phase 4
32 Lipid Regulating Agents Phase 4
33 Angiotensin II Type 1 Receptor Blockers Phase 4
34 Angiotensin Receptor Antagonists Phase 4
35 Angiotensin-Converting Enzyme Inhibitors Phase 4
36 Angiotensinogen Phase 4
37 Antihypertensive Agents Phase 4
38 diuretics Phase 4
39 Natriuretic Agents Phase 4
40 Sodium Chloride Symporter Inhibitors Phase 4
41 Analgesics, Opioid Phase 4
42 Anesthetics Phase 4,Phase 1,Phase 2
43 Anesthetics, General Phase 4
44 Anesthetics, Inhalation Phase 4
45 Anesthetics, Intravenous Phase 4
46 Central Nervous System Depressants Phase 4
47 Hypnotics and Sedatives Phase 4
48 Narcotics Phase 4
49
Alprostadil Approved, Investigational Phase 2 745-65-3 149351
50 Anticoagulants Phase 2

Interventional clinical trials:

(show all 13)

# Name Status NCT ID Phase Drugs
1 Sufficient Treatment of Peripheral Intervention by Cilostazol Unknown status NCT00912756 Phase 4 cilostazol
2 Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker Completed NCT00823849 Phase 4 Cilostazol;Probucol;Cilostazol+Probucol
3 Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study) Completed NCT00149227 Phase 4 Valsartan;Non-ARB
4 Diuretics In the Management of Essential Hypertension (DIME) Study Completed NCT00131846 Phase 4 Thiazide diuretics;No diuretics
5 Effects of Anesthetics on Postoperative Cognitive Function of Patients Undergoing Endovascular Repair of Aortic Aneurysm and Endovascular Treatment of Arteriosclerosis Obliterans of Lower Extremities. Recruiting NCT02107170 Phase 4 Sevoflurane;Propofol;Remifentanil
6 TACT-NAGOYA: Therapeutic Angiogenesis Using Cell Transplantation Unknown status NCT00145262 Phase 2
7 Autologous Bone Marrow For Lower Extremity Ischemia Treating Completed NCT00753025 Phase 2
8 A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans Recruiting NCT02877173 Phase 2 Alprostadil Liposomes for Injection;Alprostadil Injection
9 Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI) Recruiting NCT02501018 Phase 2 SOC
10 Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb Ischemia Enrolling by invitation NCT02864654 Phase 1, Phase 2
11 Preoperative Heart Rate Variability and Baroreflex Sensitivity in ASO Patients During Various Sleep Stages Completed NCT00712946
12 HELP-Apheresis in Diabetic Ischemic Foot Treatment (H.A.D.I.F) Completed NCT01518205
13 Arterial Calcification in the Diabetes Active, not recruiting NCT02431234

Search NIH Clinical Center for Arteriosclerosis Obliterans

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: arteriosclerosis obliterans

Genetic Tests for Arteriosclerosis Obliterans

Anatomical Context for Arteriosclerosis Obliterans

MalaCards organs/tissues related to Arteriosclerosis Obliterans:

38
Heart, Bone, Bone Marrow, Smooth Muscle, Skin, Endothelial, T Cells

Publications for Arteriosclerosis Obliterans

Articles related to Arteriosclerosis Obliterans:

(show top 50) (show all 244)
# Title Authors Year
1
MicroRNA-31 promotes arterial smooth muscle cell proliferation and migration by targeting mitofusin-2 in arteriosclerosis obliterans of the lower extremitie. ( 29403548 )
2018
2
The Association between Polymorphism of CARD8 rs2043211 and Susceptibility to Arteriosclerosis Obliterans in Chinese Han Male Population. ( 28135700 )
2017
3
Mir-22-3p Inhibits Arterial Smooth Muscle Cell Proliferation and Migration and Neointimal Hyperplasia by Targeting HMGB1 in Arteriosclerosis Obliterans. ( 28848136 )
2017
4
Baseline Characterization of Japanese Peripheral Arterial Disease Patientsa88- Analysis of Surveillance of Cardiovascular Events in Antiplatelet-Treated Arteriosclerosis Obliterans Patients in Japan (SEASON). ( 26841805 )
2016
5
A Rare Complication of Spinal Cord Ischemia Following Endovascular Aneurysm Repair of an Infrarenal Abdominal Aortic Aneurysm with Arteriosclerosis Obliterans: Report of a Case. ( 27738476 )
2016
6
Emerging Novel Biomarkers for Arteriosclerosis Obliterans. ( 26632166 )
2016
7
MicroRNA-133a in the Development of Arteriosclerosis Obliterans. ( 25740337 )
2015
8
Altered Plasma MicroRNAs as Novel Biomarkers for Arteriosclerosis Obliterans. ( 26370316 )
2015
9
Investigating the Role of the Posttranscriptional Gene Regulator MiR-24- 3p in the Proliferation, Migration and Apoptosis of Human Arterial Smooth Muscle Cells in Arteriosclerosis Obliterans. ( 26159387 )
2015
10
Logistic Regression Analysis of Depression in Arteriosclerosis Obliterans Patients and Its Risk Factors. ( 26564507 )
2015
11
Beraprost Sodium Protects Against Diabetic Nephropathy in Patients with Arteriosclerosis Obliterans: A Prospective, Randomized, Open-label Study. ( 25959199 )
2015
12
Involvement of MicroRNA-133a in the Development of Arteriosclerosis Obliterans of the Lower Extremities via RhoA Targeting. ( 25445891 )
2014
13
MiR-142-3p attenuates the migration of CD4a8_ T cells through regulating actin cytoskeleton via RAC1 and ROCK2 in arteriosclerosis obliterans. ( 24743945 )
2014
14
Relationship between Arteriosclerosis Obliterans and the Ratio of Serum Eicosapentaenoic Acid to Arachidonic Acid. ( 23364231 )
2013
15
Prospective study of sarpogrelate hydrochloride on patients with arteriosclerosis obliterans. ( 23364237 )
2013
16
Long-term effects of beraprost sodium on arteriosclerosis obliterans: a single-center retrospective study of Japanese patients. ( 23749750 )
2013
17
Retrograde perfusion of the hind leg in diabetic patients suffering from arteriosclerosis obliterans: theoretical considerations of oxygen supply and lymphatic flow based on rat models. ( 22259111 )
2012
18
A randomized, open-label, multicentre study to evaluate plasma atherosclerotic biomarkers in patients with type 2 diabetes mellitus and arteriosclerosis obliterans when treated with Probucol and Cilostazol. ( 23097651 )
2012
19
Increment of cerebral blood flow by LDL-apheresis in dialysis patients with arteriosclerosis obliterans: a pilot study. ( 23065872 )
2012
20
MicroRNA-21 regulates vascular smooth muscle cell function via targeting tropomyosin 1 in arteriosclerosis obliterans of lower extremities. ( 21817107 )
2011
21
The efficacy of oral beraprost sodium, a prostaglandin I2 analogue, for treating intermittent claudication in patients with arteriosclerosis obliterans. ( 20357749 )
2010
22
Study design of SEASON registry: prospective Surveillance of cardiovascular Events in an Antiplatelet-treated arterioSclerosis Obliterans patients in JapaN )SEASON). ( 20966606 )
2010
23
Current status of the medical expenses for the treatment of arteriosclerosis obliterans in Japan. ( 20357751 )
2010
24
Characteristics of revascularization treatment for arteriosclerosis obliterans in patients with and without hemodialysis. ( 20938099 )
2010
25
Tc-99m-MIBI scintigraphy in evaluating the effect of hepatocyte growth factor gene therapy for peripheral arteriosclerosis obliterans. ( 19225945 )
2009
26
[Evaluation of proinflammatory cytokines in chronic lower limb ischaemia diabetic macroangiopathy and arteriosclerosis obliterans]. ( 20120706 )
2009
27
Long-term follow-up of Symphony nitinol stents in iliac arteriosclerosis obliterans. ( 18270875 )
2008
28
Arteriosclerosis obliterans associated with anti-cardiolipin antibody/beta2-glycoprotein I antibodies as a strong risk factor for ischaemic heart disease in patients with systemic lupus erythematosus. ( 18375400 )
2008
29
Serum adiponectin and markers of endothelial injury in hemodialysis patients with arteriosclerosis obliterans. ( 18175063 )
2008
30
Changes in the activities of daily living (ADL) in relation to the level of amputation of patients undergoing lower extremity amputation for arteriosclerosis obliterans (ASO). ( 18724029 )
2008
31
Detecting vulnerable plaque of arteriosclerosis obliterans by multidetector-row computed tomography--comparing with VH (virtual histology)-intravascular ultrasound. ( 17512620 )
2008
32
Efficacy of low-density lipoprotein apheresis in arteriosclerosis obliterans of the lower extremities: two cases with marked alleviation of clinical symptoms. ( 17610290 )
2007
33
Serum levels of S-glutathionylated proteins as a risk-marker for arteriosclerosis obliterans. ( 17186986 )
2007
34
Effects of selective LDL apheresis on plasma concentrations of ICAM-1, VCAM-1 and P-selectin in diabetic patients with arteriosclerosis obliterans and receiving maintenance hemodialysis. ( 17126824 )
2007
35
Intractable wounds caused by arteriosclerosis obliterans with end-stage renal disease treated by aggressive debridement and epidermal grafting. ( 17637445 )
2007
36
Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. ( 18064333 )
2007
37
Quality of life improvement and long-term effects of peripheral blood mononuclear cell transplantation for severe arteriosclerosis obliterans in diabetic patients on dialysis. ( 17652880 )
2007
38
Cost-effectiveness of Liple (LipoPGE1) for arteriosclerosis obliterans patients in Japan: an economic evaluation using the EQ-5D instrument. ( 16763534 )
2006
39
Angiotensin I-converting enzyme inhibitor improves reactive hyperemia in elderly hypertensives with arteriosclerosis obliterans. ( 17249520 )
2006
40
Autoperipheral blood mononuclear cell transplantation improved giant ulcers due to chronic arteriosclerosis obliterans. ( 16865304 )
2006
41
Close association of hypoadiponectinemia with arteriosclerosis obliterans and ischemic heart disease. ( 15877296 )
2005
42
Prevalence of asymptomatic arteriosclerosis obliterans and its relationship with risk factors in inhabitants of rural communities in Japan: Tanno-Sobetsu study. ( 15488869 )
2004
43
Clinical application of bone marrow implantation in patients with arteriosclerosis obliterans, and the association between efficacy and the number of implanted bone marrow cells. ( 15564705 )
2004
44
Effect of the serotonin blocker sarpogrelate on circulating interleukin-18 levels in patients with diabetes and arteriosclerosis obliterans. ( 15080020 )
2004
45
Autologous transplantation of peripheral blood stem cells as an effective therapeutic approach for severe arteriosclerosis obliterans of lower extremities. ( 14983238 )
2004
46
Low-density lipoprotein apheresis in a patient with arteriosclerosis obliterans and light chain deposition disease. ( 15224807 )
2004
47
Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamole. ( 15203718 )
2004
48
Three cases of ischemic ulcer due to arteriosclerosis obliterans responding to basic fibroblast growth factor spray. ( 15372302 )
2004
49
The effect of Liple on physical and emotional quality of life in the treatment of arteriosclerosis obliterans. ( 15765038 )
2004
50
Effects of LDL apheresis and vitamin E-modified membrane on carotid atherosclerosis in hemodialyzed patients with arteriosclerosis obliterans. ( 12886046 )
2003

Variations for Arteriosclerosis Obliterans

Expression for Arteriosclerosis Obliterans

Search GEO for disease gene expression data for Arteriosclerosis Obliterans.

Pathways for Arteriosclerosis Obliterans

Pathways related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.08 HGF HIF1A ICAM1 IL6 VCAM1
2 12.16 ICAM1 IL6 VCAM1
3 11.89 ICAM1 SELP VCAM1
4 11.84 HGF IL6 VCAM1
5 11.81 ADIPOQ HIF1A IL6
6 11.75 ICAM1 MCAM VCAM1
7 11.73 ICAM1 IL6 SELP
8 11.67 ICAM1 IL6 VCAM1
9 11.6 ICAM1 IL6 VCAM1
10 11.44 ADIPOQ IL6 MCAM VCAM1
11 11.41 HGF HIF1A ICAM1 IL6 VCAM1
12 11.4 ICAM1 IL6 VCAM1
13
Show member pathways
11.34 ICAM1 IL6 VCAM1
14 11.23 ICAM1 VCAM1
15 11.18 ICAM1 IL6 SELP
16 10.98 ICAM1 IL6 VCAM1
17 10.9 ADIPOQ IL6
18 10.73 ICAM1 VCAM1
19 10.71 HGF ICAM1 IL6 SELP VCAM1

GO Terms for Arteriosclerosis Obliterans

Cellular components related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.26 ICAM1 MCAM SELP VCAM1
2 extracellular space GO:0005615 9.17 ADIPOQ HGF ICAM1 IL6 MCAM SELP

Biological processes related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.84 ICAM1 MCAM SELP VCAM1
2 response to lipopolysaccharide GO:0032496 9.7 ICAM1 SELP VCAM1
3 response to ethanol GO:0045471 9.58 ADIPOQ ICAM1 VCAM1
4 negative regulation of I-kappaB kinase/NF-kappaB signaling GO:0043124 9.57 ADIPOQ CARD8
5 epithelial to mesenchymal transition GO:0001837 9.56 HGF HIF1A
6 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.55 HGF ICAM1
7 positive regulation of chemokine production GO:0032722 9.51 HIF1A IL6
8 calcium-mediated signaling using intracellular calcium source GO:0035584 9.49 SELP VCAM1
9 negative regulation of tumor necrosis factor-mediated signaling pathway GO:0010804 9.48 ADIPOQ CARD8
10 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.46 ADIPOQ TPM1
11 response to hypoxia GO:0001666 9.46 ADIPOQ HIF1A ICAM1 VCAM1
12 leukocyte tethering or rolling GO:0050901 9.43 SELP VCAM1
13 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.43 ICAM1 SELP VCAM1
14 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.37 ADIPOQ TPM1
15 membrane to membrane docking GO:0022614 9.32 ICAM1 VCAM1
16 leukocyte cell-cell adhesion GO:0007159 9.13 ICAM1 SELP VCAM1
17 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 8.92 ADIPOQ HGF ICAM1 IL6

Molecular functions related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sialic acid binding GO:0033691 8.62 ADIPOQ SELP

Sources for Arteriosclerosis Obliterans

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....